KR101876617B1 - Composition comprising extract of Ilex cornuta for promoting the differentiation to adipocytic cells - Google Patents
Composition comprising extract of Ilex cornuta for promoting the differentiation to adipocytic cells Download PDFInfo
- Publication number
- KR101876617B1 KR101876617B1 KR1020150186190A KR20150186190A KR101876617B1 KR 101876617 B1 KR101876617 B1 KR 101876617B1 KR 1020150186190 A KR1020150186190 A KR 1020150186190A KR 20150186190 A KR20150186190 A KR 20150186190A KR 101876617 B1 KR101876617 B1 KR 101876617B1
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- extract
- ilex
- cosmetic composition
- stem cells
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 230000004069 differentiation Effects 0.000 title claims abstract description 42
- 235000002710 Ilex cornuta Nutrition 0.000 title claims abstract description 18
- 241001310146 Ilex cornuta Species 0.000 title claims abstract description 18
- 239000000284 extract Substances 0.000 title claims description 61
- 230000001737 promoting effect Effects 0.000 title abstract description 20
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 50
- 102000011690 Adiponectin Human genes 0.000 claims abstract description 26
- 108010076365 Adiponectin Proteins 0.000 claims abstract description 26
- 235000018388 Ilex x wandoensis Nutrition 0.000 claims abstract description 26
- 241001070197 Ilex x wandoensis Species 0.000 claims abstract description 26
- 230000001965 increasing effect Effects 0.000 claims abstract description 24
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 14
- 230000037303 wrinkles Effects 0.000 claims abstract description 13
- 230000032683 aging Effects 0.000 claims abstract description 10
- 230000009759 skin aging Effects 0.000 claims abstract description 5
- 210000003491 skin Anatomy 0.000 claims description 44
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 42
- 239000002537 cosmetic Substances 0.000 claims description 35
- 210000004003 subcutaneous fat Anatomy 0.000 claims description 21
- 241000209035 Ilex Species 0.000 claims description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 7
- 210000002744 extracellular matrix Anatomy 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 210000004207 dermis Anatomy 0.000 claims description 4
- 238000000465 moulding Methods 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 abstract description 17
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 14
- 208000030159 metabolic disease Diseases 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 13
- 238000000034 method Methods 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 7
- 230000006872 improvement Effects 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 22
- 241000208422 Rhododendron Species 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 108010016731 PPAR gamma Proteins 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 9
- 235000013399 edible fruits Nutrition 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 8
- 229960002986 dinoprostone Drugs 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 235000003332 Ilex aquifolium Nutrition 0.000 description 5
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 5
- 235000002294 Ilex volkensiana Nutrition 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 201000009273 Endometriosis Diseases 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000000536 PPAR gamma Human genes 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 208000004104 gestational diabetes Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 102000014777 Adipokines Human genes 0.000 description 2
- 108010078606 Adipokines Proteins 0.000 description 2
- 235000003840 Amygdalus nana Nutrition 0.000 description 2
- 244000296825 Amygdalus nana Species 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 235000011432 Prunus Nutrition 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000478 adipokine Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000004719 natural immunity Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000014774 prunus Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- 241000209034 Aquifoliaceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000057001 Balanites aegyptiaca Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000003325 Ilex Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710186630 Insulin-1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 241000736131 Sphingomonas Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000016438 regulation of fat cell differentiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/76—Undefined extracts from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to a process for the production of Ilex cornuta , Ilex x wandoensis ) composition for prevention of skin wrinkles and skin aging, and a composition for preventing or treating metabolic diseases, and more particularly, to a composition for promoting adipocyte differentiation and increasing adipose tissue Is useful not only for prevention of aging, skin aesthetics or skin formation but also for preventing or treating metabolic diseases through improvement of insulin sensitivity by increasing adiponectin secretion.
Description
The present invention relates to a process for the production of Ilex cornuta , Ilex x wandoensis ) extracts. In particular, it promotes the differentiation of mesenchymal stem cells into adipocytes and increases secretion of adiponectin, which can be used as a composition for improving skin wrinkles and preventing skin aging. In addition, the extract of the present invention can be used as an effective composition for prevention and treatment of metabolic diseases by promoting secretion of adiponectin and enhancing insulin sensitivity.
Tiger of the invention thorns (Ilex cornuta , Ilex x wandoensis ) extract promotes adipocyte differentiation in subcutaneous adipose tissue, thereby increasing the subcutaneous fat layer or maintaining the adipocyte that decreases with aging of the skin, thereby increasing the elasticity of the skin, have. The increase in the subcutaneous fat layer can be used in cosmetic surgery fields such as wrinkle improvement and prevention of skin sagging (Hu S et al., Ann Plast Surg 2007 Jun; 58 (6): 602-607; Yoshimura K et al. Aesthetic Plast Surg. 2008; 32 (1): 48-55). Recently, it has been known that adipose tissue of skin dermis and subcutaneous fat plays an important role in natural immunity (innate immunity) to protect skin from external bacteria or skin fungus (Zhang et al., Science 2015, 347: 67-71.), Maintenance and protection of skin fat tissue is very important for skin immunity function in addition to skin beauty.
Subcutaneous adipose tissue plays a role in the volume and intensity of the skin. Especially, the skin of the face part decreases in thickness as the aging progresses, which causes wrinkles and elasticity decrease (Fenske et al., J Am Acad Dermatol 1986, 15: 571-585; Rho et al., Bioorg Med Chem Lett., 2014, 24 (9): 2141-2145). In addition, redistribution of body fat due to metabolic abnormalities such as hormones, blood, fat and bones appearing in postmenopausal women not only negatively affects skin beauty but also increases the incidence of metabolic diseases. Recently, plastic surgery for transplanting adipocytes into the skin has been widely carried out. Fat transplantation, which is sometimes referred to as lipofilling, is used for wrinkles of aging skin, correction of nose, chin and forehead lines, depressed skin due to burns or wounds, and areas lost by cancer resection surgery. However, there is a problem in that 40-60% of the transplant volume is lost after transplantation (S Eremia et al., 2000, Dermatol. Sur. 26, 1150-1158; Fulton JE et al., 2001, Dermatol. 3), 523-530). Therefore, there is a need for a method for a composition that, when transplanted with subcutaneous fat, can maintain or increase the transplantation of adipose tissue.
Most cosmetic products that are expected to improve wrinkles and skin elasticity to date are those that focus on increasing dermal collagen, inhibiting collagen-degrading enzymes, or regulating the homeostasis of the extracellular matrix to be. However, considering that the basic structure of the skin is maintained by the volume of subcutaneous fat tissue, increasing the volume of adipose tissue to maintain volume and resilience of the skin may be another solution. Recently, adiponectin, which is mainly produced in adipocytes, has been reported to promote the biosynthesis of extracellular matrix (ECM) and collagen of dermal fibroblast (Ezure and Amano. Biofactors 2007, 31: 229-236. ). Therefore, compositions that increase subcutaneous fat or increase adiponectin biosynthesis can be used as cosmetics to prevent aging, skin cosmetic agents, adjuvants for skin molding implants, and the like.
Adiponectin, one of the representative adipokines secreted from adipocytes during adipocyte differentiation, has been reported to be effective in treating metabolic diseases that improve insulin resistance in diabetes (Yamauchi et al., Nat Med. 2001, 7 (8): 941-946). In particular, in diabetes, adiponectin has the effect of preventing diabetes by lowering blood glucose by increasing insulin sensitivity. Therefore, substances that increase the expression of adiponectin during the adipocyte differentiation process can be expected to prevent and cure diabetes. In addition, many studies have shown that lowering of adiponectin causes diseases such as gestational diabetes, pancreatic cancer, hyperlipidemia, fatty liver, chronic kidney disease and endometriosis.
In studying the effect of improving insulin sensitivity, since lipid precursor cells have the property of being differentiated into adipocytes in the presence of inducer such as insulin, the presence of an insulin-like substance (insulin substance) (Shin et al., Biochem. Pharmacol. 2009, 77: 125-133). Recently, mesenchymal stem cells as well as preadipocytes have been used to search for natural products that are expected to have preventive or therapeutic effects on metabolic diseases (Shin et al., Biochem. Pharmacol. 2009, 77 : 125-133; Noh, Biochem. Pharmacol., 2012, 83: 661-670). In particular, mesenchymal stem cells can be obtained from subcutaneous tissues and differentiated into adipocytes (Xu et al., Exp. Cell Res 2006, 312: 1856-1864). In subcutaneous fat, (Cnop et al., Diabetes 2002, 51 (4): 1005-1015). It has been suggested recently that there is no evidence that insulin resistance is independent of insulin resistance in type 2 diabetes. That is, in terms of insulin sensitivity, the increase in subcutaneous fat is advantageous in terms of skin beauty and natural immunity when compared to abdominal fat or visceral fat. Therefore, compositions for increasing subcutaneous fat include anti-aging cosmetics and skin health Can help. Accordingly, the inventors of the present invention have found that, while researching and searching for a natural product having no toxicity in vivo, the extract of Pricklewood extract promotes the differentiation of mesenchymal stem cells into adipocytes and at the same time increases the expression of adiponectin, It was completed.
Tiger of the invention thorns (Ilex cornuta , Ilex x wandoensis ) is a dicotyledonous plant belonging to the Aquifoliaceae and grows up to 4 ~ 5m in height. The leaves are thick oval hexagonal shape with the tip of the corner being spiny, and the red fruit ripens from September to October. It grows in the southern hemisphere of South Korea, Wando, and Jeju Island. In one room, leaves and fruits are used as medicines. Leaves have the effect of strong winds and tangles, the fruits have gingko effect, and help the circulation of blood ("Sanayasu for the body", Nov. 15, 2009, Nexus Co., Ltd.). However, Adiponectin biosynthesis and promotion of lipid differentiation have not been reported.
The present inventors have studied and studied in natural products in order to promote the differentiation of adipocytes constituting adipose tissue and increase the biosynthesis of adiponectin thereby to increase the volume of skin, The inventors of the present invention have discovered an effect of promoting the differentiation of adipocytes and increasing the biosynthesis of adiponectin, and as a result, they have been able to maintain the elasticity of the skin continuously and improve the wrinkles. However, the above-mentioned effect of promoting differentiation of adipocytes is not limited to a specific adipose tissue of the body, and may include, for example, a breast region of a woman having many fat layers. The present invention relates to the regulation of adipocyte differentiation, and more specifically, to promote the differentiation of mesenchymal stem cells (MSC) into adipocytes, thereby exhibiting not only skin cosmetic and cosmetic effects but also metabolic disease prevention and therapeutic efficacy ≪ / RTI >
It is an object of the present invention to provide a process for the preparation & cornuta , Ilex x wandoensis ) as a composition for promoting differentiation of adipocytes. Another object of the present invention is to provide a composition for external application of skin for cosmetic and cosmetic purposes based on such an effect and to provide a pharmaceutical composition for preventing and treating early metabolic diseases in which diabetes or insulin sensitivity is deteriorated and its use as health functional food . However, the application site of the composition for external application for skin due to the promotion effect of the adipocyte differentiation includes all the adipose tissues of the body, and is not limited to a specific site.
In order to achieve the above object, the present invention holly (Ilex cornuta , Ilex x wandoensis ) extract of the present invention.
The present invention also relates to a method for producing cornuta , Ilex x wandoensis ) extract.
The present invention also relates to a method for producing cornuta , Ilex x wandoensis ) extract increases fat cells.
The present invention also relates to a method for producing cornuta , Ilex x wandoensis ) extract increases fat cells to improve skin wrinkles and prevent skin aging.
The present invention also relates to a method for producing cornuta , Ilex x wandoensis ) extract. The present invention also provides a composition for adjuvant of lipofilling.
The present invention also relates to a method for producing cornuta , Ilex x wandoensis ) extract of the present invention.
The present invention also relates to a method for producing cornuta , Ilex x wandoensis ) extract for preventing and / or ameliorating a metabolic disease.
The present invention relates to a process for the production of Ilex cornuta , Ilex x wandoensis ) is effective for promoting differentiation of adipocytes, and thus is useful for improving wrinkles of skin, preventing aging of skin, increasing adipose tissue for skin care or skin molding, and improving metabolism through improvement of insulin sensitivity Can be usefully used for preventing or treating diseases.
Figure 1 is a cross- Effect of hAT-MSC (human adipose tissue-derived MSC) on lipid differentiation by extracts of cornuta , Ilex x wandoensis . MSC for the evaluation of the effect of promoting fat differentiation by oil red o staining.
FIG. 2 is a graph showing the effect of hAT-MSC on the stimulation of adiponectin biosynthesis by the extract of Verdant.
FIG. 3 is a graph showing the degree of relative binding of a ferret extract to a peroxisome proliferator-activated receptor gamma (PPARγ).
Fig. 4 is a graph showing the inhibitory effect of prostaglandin E2 (prostaglandin E2, PGE2) biosynthesis by the extract of the rhododendron.
Hereinafter, the present invention will be described in detail.
It is preferred, but not limited, to be produced by a process comprising the following steps:
1) extracting an extract of Solanaceae with an extraction solvent;
2) filtering the extract of step 1);
3) The step of filtration of the filtered extract of step 2), followed by drying, to prepare a Rhododendron sp.
In the above method, the fruit of step 1) can be used without limitation such as cultivated or commercially available, and leaves, roots, stems and branches can be used.
In the above method, it is preferable to use water, an alcohol or a mixture thereof and an organic solvent as the extraction solvent in step 1). As the alcohol, it is preferable to use a C 1 to C 2 lower alcohol. As the extraction method, it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but it is not limited thereto. The extraction solvent is preferably added by 1 to 10 times the amount of dried rhododendron, and more preferably 4 to 6 times by volume. The extraction temperature is preferably 20 to 100 캜, more preferably 20 to 40 캜. The extraction time is preferably 10 to 48 hours, more preferably 15 to 30 hours, most preferably 24 hours. In addition, the number of times of extraction is preferably 1 to 5 times, more preferably 3 to 4 times, and most preferably 3 times.
Further, in the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator, but not limited thereto. The drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.
The present invention provides a composition for promoting adipocyte differentiation comprising an extract of Ilex species as an active ingredient.
The holly tree holly (Ilex cornuta and Ilex x wandoensis .
The composition is characterized by exhibiting an effect of increasing the adipose tissue, and the increasing effect of the adipose tissue may be for cosmetic or cosmetic purposes, but is not limited thereto.
The composition is characterized in promoting the differentiation of mesenchymal stem cells into adipocytes, wherein the mesenchymal stem cells are preferably human mesenchymal stem cells, and the human mesenchymal stem cells Are preferably mesenchymal stem cells derived from human skin dermal and subcutaneous fat.
The composition promotes the differentiation from the subcutaneous fat layer into the adipocyte, thereby maintaining the thickness of the subcutaneous fat layer that decreases with the progress of aging, promotes collagen and ECM (extracellular matrix) synthesis of skin dermis by increasing adiponectin biosynthesis, , Restoration and strengthening of the skin elasticity, and a function of increasing the sense of volume. However, these effects are not limited to specific subcutaneous fat layers of the body. That is, the effect of increasing the adipose tissue is not limited to the effect of increasing adipose tissue for cosmetic or cosmetic purposes.
In a particular embodiment of the present invention, the inventors holly (Ilex cornuta , Ilex x wandoensis ), and then treated with mesenchymal stem cells to induce differentiation of adipocytes without inducing apoptosis (see FIG. 1).
As a result of quantitative measurement of adipocyte differentiation promoting effect by measuring adiponectin expression, the expression level of adiponectin was significantly increased in the test group treated with Rhododendron sp. (See FIG. 2).
In addition, in order to confirm the molecular mechanism of the extract of Rhododendron rhizome, the extracts of Rhododendron rhizoma extract and the peroxisome proliferator activated receptor gamma were examined. The rhizomorphous Rhizome extracts play an important role in promoting lipid differentiation and improving insulin sensitivity (See Table 1 and FIG. 3). ≪ Desc / Clms Page number 2 >
Finally, as a result of confirming the anti-inflammatory effect of Rhododendron rhizome extract, it was confirmed that the Rhizomaceae extract inhibited the biosynthesis of prostaglandin E2 and PGE2 to exhibit an anti-inflammatory effect (see FIG. 4) The extracts of Prunus persicae may be useful for the promotion of adipocyte differentiation and for the prevention and treatment of metabolic diseases.
The present invention also relates to a method for producing cornuta , Ilex x wandoensis ) extract.
Preferably, the extract is extracted with water, a C 1 to C 2 lower alcohol or a mixture thereof.
The composition is characterized by exhibiting an effect of increasing the adipose tissue, and the increasing effect of the adipose tissue may be for cosmetic or cosmetic purposes, but is not limited thereto.
The composition is characterized in promoting the differentiation of mesenchymal stem cells into adipocytes, wherein the mesenchymal stem cells are preferably human mesenchymal stem cells, and the human mesenchymal stem cells Are preferably mesenchymal stem cells derived from human skin dermal and subcutaneous fat.
The cosmetic composition of the present invention is characterized by increasing fat cells to improve skin wrinkles and prevent skin aging.
Also, the cosmetic composition of the present invention is used as an adjuvant of lipofilling.
When the composition of the present invention is used as a cosmetic composition for improving skin wrinkles and preventing aging, the composition is not particularly limited depending on the body part. Specifically, it may be a cosmetic composition having a formulation of a softening agent, a nutritional lotion, a massage cream, a nutritional cream, a pack, a gel or a skin adhesive type cosmetic composition and may be a cosmetic composition such as a lotion, ointment, gel, cream, patch or spray It may be a transdermal dosage form.
The cosmetic composition for improving skin wrinkles and preventing aging according to the present invention may further contain, in addition to the extract of the present invention, a fat substance, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a surfactant, a water, an ionic or nonionic emulsifier, a filler, a sequestering and chelating agent, a preservative, a vitamin, a barrier, a wetting agent, an essential oil, a dye, a pigment, a hydrophilic or lipophilic active agent, Such as lipid vesicles or any other ingredient conventionally used in compositions for the improvement of skin aesthetics. In addition, the components can be introduced in amounts commonly used in the dermatology field.
The cosmetic composition according to the present invention contains Rhododendron bark extract as an active ingredient in an amount of 0.0001 to 30% by weight based on the total weight of the cosmetic composition. In addition, the components other than the above-described extract of the fruit of the present invention can be mixed with each other without difficulty by those skilled in the art according to the formulation or use purpose of other external preparations for skin, and in this case, A synergistic effect can occur.
The present invention also relates to a method for producing cornuta , Ilex x wandoensis ) extract of the present invention.
Preferably, the extract is extracted with water, a C 1 to C 2 lower alcohol or a mixture thereof.
The composition is characterized in promoting the differentiation of mesenchymal stem cells into adipocytes, wherein the mesenchymal stem cells are preferably human mesenchymal stem cells, and the human mesenchymal stem cells Are preferably mesenchymal stem cells derived from human skin dermal and subcutaneous fat.
The composition is characterized in that it increases adiponectin.
The metabolic diseases are preferably selected from the group consisting of obesity, diabetes, gestational diabetes, pancreatic cancer, hyperlipidemia, hypercholesterolemia, arteriosclerosis, fatty liver, chronic renal disease, endometriosis and cardiovascular disease.
In a particular embodiment of the present invention, the inventors holly (Ilex cornuta , and Ilex x wandoensis ), and the extract of Trichinaceae was promoted to differentiate into adipocytes (see FIG. 1) (See FIG. 2), the extract of the present invention can be useful for the prevention or treatment of metabolic diseases through improvement of insulin sensitivity.
The pharmaceutical composition may further comprise a pharmaceutically acceptable additive. The additive may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
The pharmaceutical dosage forms of the compositions of the present invention may also be used in the form of their pharmaceutically acceptable salts and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable set.
The pharmaceutical preparations containing the composition according to the present invention can be administered orally in the form of oral preparations such as tablets, pills, capsules, powders, suspensions, granules or expectorates, external preparations, suppositories and sterile injection solutions according to conventional methods And can be used as formulations.
The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount. There is no particular restriction on the dosage, and it may vary depending on the body's absorption, body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, severity of disease and the like. The pharmaceutical composition of the present invention is prepared in consideration of an effective dose range, and the unit dosage formulations thus formulated are classified according to the judgment of the expert who monitors or observes the administration of the drug, if necessary, Or may be administered several times at a predetermined time interval. Preferably, the composition of the present invention may be administered at a dose of 0.5 to 5000 mg / kg, preferably 50 to 500 mg / kg, more preferably 50 mg / kg, per day, based on the amount of the fruit of Rhododendron The above administration may be administered once a day, or may be administered several times.
The composition of the present invention can be administered to mammals such as poultry, rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
The present invention also relates to a method for producing cornuta , Ilex x wandoensis ) extract of the present invention for the prevention and improvement of metabolic diseases.
Preferably, the extract is extracted with water, a C 1 to C 2 lower alcohol or a mixture thereof.
The composition is characterized in promoting the differentiation of mesenchymal stem cells into adipocytes, wherein the mesenchymal stem cells are preferably human mesenchymal stem cells, and the human mesenchymal stem cells Are preferably mesenchymal stem cells derived from human skin dermal and subcutaneous fat.
The composition is characterized in that it increases adiponectin.
The metabolic diseases are preferably selected from the group consisting of obesity, diabetes, gestational diabetes, pancreatic cancer, hyperlipidemia, hypercholesterolemia, arteriosclerosis, fatty liver, chronic renal disease, endometriosis and cardiovascular disease.
As used herein, the term "health functional food" is produced by using raw materials or ingredients (functional raw materials) having functions useful for nutrients or human body that are likely to be deficient in daily eating, and is intended to maintain the normal function of the human body, But is not limited to, and is not meant to exclude health food in the usual sense.
Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.
However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the contents of the present invention are not limited by the following Examples and Experimental Examples.
< Example 1 > Preparation of the extract of the rhododendron
Thorn tree ( Ilex : Ilex cornuta , Ilex x wandoensis , domestic) extracts were evaluated for the promotion of adipocyte differentiation by the ethanol extract of Taurine tree provided by the National Institute of Horticultural Science, Rural Development Administration.
Specifically, Ilex cornuta , Ilex x wandoensis ) and 30 g of ethanol were added to 200 ml of ethanol (95.0-95.5 v / v%). Then, the mixture was treated with an
< Experimental Example 1> Origin of human fat Mesenchymal stem cells Cultivation and identification of the effect of promoting the differentiation of adipocyte from Rhododendron sp.
Human adipose tissue derived mesenchymal stem cells (hAT-MSCs) were purchased from Lonza, Inc. (Walkersville, MD, USA) and cultured according to Lonza's guidelines. Adipocyte differentiation of hAT-MSCs was induced according to the guidelines of Lonza Inc. with the exception of indomethacin.
Specifically, hAT-MSC was differentiated into adipocytes by incubating 1 μg / ml of insulin, 1 μM of dexamethasone (DEXA) and 0.5 mM of isobutylmethylxanthine (IBMX) in the culture medium of mesenchymal stem cells , And in the experimental group, when the adipocyte differentiation induction was induced, Rhizoma extract was added to the medium at a proper concentration. Glucenclamide (10 μM) and aspirin (300 μM) were used as positive controls, and treated with IDX (Insulin 1 μg / ml + dexamethasone 1 μM + isobutylmethylxanthine 0.5 mM) medium. After 14 days from the start of adipocyte differentiation of mesenchymal stem cells, the cell culture medium was removed, and the cells were washed with 10 ml of phosphate buffered saline (PBS). Then, 10 ml of a 10% formalin / PBS solution of 0.2 ml / cm 2 was used to fix the cells for 10 minutes. The immobilized cells were washed once with a 60% isopropanol solution 0.5 ml / cm 2 , and the lipid in the adipocyte was stained with 0.2 ml / cm 2 of a dye solution obtained by dissolving Oil Red O in 60% isopropanol Respectively. Subsequently, re-staining was performed with hematoxylin to make it easy to distinguish the nucleus, and then observed with a microscope. The observation result is shown in Fig.
As shown in Fig. 1, the extracts of Prickleberry extract promoted differentiation into adipocytes without inducing apoptosis of mesenchymal stem cells (Fig. 1).
< Experimental Example 2> The effect of human Of mesenchymal stem cells Quantitative measurement of promoting effect of adipocyte differentiation
After the induction of differentiation of adipocytes from mesenchymal stem cells as described in Example 1 and the last medium change after 2 days, the amount of adiponectin expressed in the cell culture supernatant was measured quantitatively A comparison was made.
Adiponectin is one of the representative adipokines secreted by adipocytes and has been reported to exhibit various effects including antidiabetic action. For example, in diabetes, adiponectin has the effect of preventing diabetes by lowering blood glucose by increasing insulin sensitivity. Such adiponectin is known to be a protein whose expression increases with the differentiation of adipocytes. Adiponectin and other cytokines were measured using the DuoSet Kit from R & D Systems, Minneapolis, Minn., USA. The results were analyzed by post hoc test after one-way analysis (ANOVA) A value of 0.05 or less indicates a significant difference.
As a result, as shown in Fig. 2, when the adipocyte differentiation was induced by IDX, the expression level of adiponectin was significantly increased in the experimental group treated with Rhododendron sp. (Fig. 2).
< Experimental Example 3> The human Of mesenchymal stem cells Identification of the molecular mechanism of the stimulation of differentiation into adipocytes
Peroxisome proliferator activated receptor gamma (PPARγ) is a nuclear receptor that plays an important role in promoting lipid differentiation and improving insulin sensitivity. In order to confirm the molecular mechanism of promoting the differentiation into the lipopolysaccharide by the Rhodiola extract, it was confirmed whether or not the Rhizomonas thunbergii extract and the peroxisome proliferator activated receptor gamma were bound to each other.
Specifically, the extract of Iris cornuta leaf extract, Ilex cornuta fruit extract and Ilex x wandoensis leaf extract) was directly added to the peroxisome proliferator-activated receptor gamma in order to determine the presence or absence of direct binding to the peroxisome proliferator-activated receptor gamma in the period of time purchased from Thermo Fisher Scientific, Inc. Waltham, Massachusetts, USA Degradation fluorescence resonance energy transfer competitive competitive peroxisome proliferator activated receptor gamma binding assay (LanthaScreen® TR-FRET PPAR gamma Competitive Binding Assay Kit) was used. As a positive control, 1 μM of GW1929, an agonist of peroxisome proliferator-activated receptor gamma, was used up to 0.001 μM by a 10-fold step-wise dilution method. For the experimental group, competitive binding was analyzed at concentrations of 50 ㎍ / ㎖, 25 ㎍ / ㎖ and 10 ㎍ / ㎖, respectively. Fluorescence was measured using an ENSIGHT (PerkinElmer) instrument from PerkinElmer, Inc. Waltham, Massachusetts, USA. The fluorescence was excited at 340 nm wavelength and fluorescence was measured at 520 nm and 495 nm wavelength, And the degree of relative bonding was quantified.
As a result, it was found that it binds to peroxisome proliferator activated receptor gamma, as shown in Table 1 and FIG. 3 (Table 1 and FIG. 3).
< Example 4> Quantitative measurement of inhibitory effect of PGE2 on induction of UV irradiation in human normal keratinocyte
Among the various inflammatory mediators, prostaglandins are the first inflammation inducers that are biosynthesized in the acute inflammatory response. Therefore, it is basically evaluated in the development of basic anti-inflammatory drugs and cosmetics new materials, and it is related to the mechanism of action of aspirin in medicines. Thus, it was confirmed that the extract of the Talon bark extract prepared in Example 1 had an effect of inhibiting the biosynthesis of prostaglandin E2 (PGE2).
Specifically, the control group without ultraviolet irradiation, the ultraviolet irradiation group, and the ultraviolet irradiation group were used as a positive control group treated with aspirin. UVB 20 mJ / cm 2 was irradiated to human normal keratinocytes and then treated with 50 ppm of 1% FBS / DMEM medium. After 18 hours, the supernatant was recovered and subjected to a prostaglandin E2 enzyme immunoassay (ELISA).
As a result, as shown in Fig. 4, the anti-inflammatory effect was confirmed by treating the Rhododendron sp. Extract with 50 μg / ml (FIG. 4).
Claims (13)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150186190A KR101876617B1 (en) | 2015-12-24 | 2015-12-24 | Composition comprising extract of Ilex cornuta for promoting the differentiation to adipocytic cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150186190A KR101876617B1 (en) | 2015-12-24 | 2015-12-24 | Composition comprising extract of Ilex cornuta for promoting the differentiation to adipocytic cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170076206A KR20170076206A (en) | 2017-07-04 |
| KR101876617B1 true KR101876617B1 (en) | 2018-08-02 |
Family
ID=59357394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150186190A KR101876617B1 (en) | 2015-12-24 | 2015-12-24 | Composition comprising extract of Ilex cornuta for promoting the differentiation to adipocytic cells |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101876617B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200104996A (en) * | 2019-02-28 | 2020-09-07 | 코스맥스 주식회사 | A composition for preventing or treating inflammation comprising an extract of Ilex cornuta and uses thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101940286B1 (en) * | 2017-11-23 | 2019-01-23 | 대한민국 | Primer Set for Identifying Maternal origin of Ilex x wandoensis and Uses Thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101001492B1 (en) * | 2008-05-01 | 2010-12-15 | 주식회사 바이오셀릭스 | Cosmetic composition for anticellulite treatments |
| KR101538136B1 (en) | 2015-01-07 | 2015-07-23 | 임종식 | Attractive pill using Lleycornuta Lind and Chondrichtiyes and making method of it |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100870263B1 (en) * | 2007-10-05 | 2008-11-25 | 박득자 | Compositions of cosmectic pack or cosmectic pack |
| US8642094B2 (en) * | 2008-05-01 | 2014-02-04 | Afexa Life Sciences Inc. | Synergistic pharmaceutical composition, method of making same and use of same |
| KR20120071841A (en) * | 2010-12-23 | 2012-07-03 | 중앙대학교 산학협력단 | Composition for treating or preventing atopic dermatitis comprising extract from ilex rotunda leaf or caffeoyl derivatives |
| KR20120135448A (en) * | 2011-06-01 | 2012-12-14 | 중앙대학교 산학협력단 | New compounds purified from the leaves of ilex rotunda and anti-oxidative effect thereof |
-
2015
- 2015-12-24 KR KR1020150186190A patent/KR101876617B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101001492B1 (en) * | 2008-05-01 | 2010-12-15 | 주식회사 바이오셀릭스 | Cosmetic composition for anticellulite treatments |
| KR101538136B1 (en) | 2015-01-07 | 2015-07-23 | 임종식 | Attractive pill using Lleycornuta Lind and Chondrichtiyes and making method of it |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200104996A (en) * | 2019-02-28 | 2020-09-07 | 코스맥스 주식회사 | A composition for preventing or treating inflammation comprising an extract of Ilex cornuta and uses thereof |
| KR102236417B1 (en) | 2019-02-28 | 2021-04-06 | 코스맥스 주식회사 | A composition for preventing or treating inflammation comprising an extract of Ilex cornuta and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170076206A (en) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9999587B2 (en) | Compositions and methods for stimulation MAGP-1 to improve the appearance of skin | |
| KR101059471B1 (en) | Cosmetic composition for skin aging | |
| KR101915952B1 (en) | Composition for anti-oxidant, anti-inflammatory and skin regeneration comprising Houttuynia cordata thumb extract as effective component | |
| KR102007762B1 (en) | Composition for skin and fur of companion animal | |
| US8557795B2 (en) | Composition containing Chamaecyparis obtusa polysaccharides to be externally applied to the skin | |
| US20220305071A1 (en) | Composition comprising prunus persica extract | |
| KR101876617B1 (en) | Composition comprising extract of Ilex cornuta for promoting the differentiation to adipocytic cells | |
| KR101033921B1 (en) | Composition for reducing irritation and inflammation in skin | |
| KR100915711B1 (en) | Moisturizing, anti-inflammatory, antibacterial or anti-allergic compositions, and preparation methods thereof | |
| WO2007081190A1 (en) | Novel use of 1,2,3,4,6-penta-o-galloyl-beta-d-glucose | |
| KR101803757B1 (en) | Cosmetic composition containing natural complex fermented extracts | |
| US20220072077A1 (en) | Composition for preventing or treating skin diseases comprising bridalwreath spirea | |
| KR102033073B1 (en) | Compositions for skin regeneration, skin soothing or wound healing comprising sericin, extracts of erect hedge parsley extract and extracts of mistletoe | |
| KR20100008541A (en) | Composition for promoting the differentiation of human mesenchymal stem cell to adipocytic cells containing the extracts of trichosanthis semen or cannabis semen | |
| KR101621499B1 (en) | Composition for increasing matrix metalloproteinase expression comprising Euphorbia lathyris extract and use thereof | |
| US11278748B2 (en) | Endothelin-converting enzyme inhibitor | |
| KR101190201B1 (en) | Cosmetic composition containing extract of pinus root | |
| KR20170045927A (en) | Anti-aging composition for skin external application comprising Potentilla chinensis Extract and Method for Preparing the Same | |
| KR20170051926A (en) | Functional food composition for preventing degenerative arthritis comprising biochanin-A derived from red clover | |
| KR101810825B1 (en) | Cosmetics compositions containing fermentation extract from leaf Daphniphyllum macropodum Miq. | |
| TWI748944B (en) | Matrix metalloproteinase production inhibitor | |
| KR100561781B1 (en) | Composition for skin whitening containing extract of Sinomenium acutum | |
| JP2011057596A (en) | Tryptase activity inhibitor and use thereof | |
| JP2022162862A (en) | filaggrin and hyaluronic acid production promoter | |
| KR20240007891A (en) | Pharmaceutical composition for treating vitiligo containing mountain-ash extract as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |